Gene: VAPB

9217
ALS8|VAMP-B|VAP-B
VAMP associated protein B and C
protein-coding
20q13.32
Ensembl:ENSG00000124164 MIM:605704 Vega:OTTHUMG00000032840 UniprotKB:O95292
NG_008073.2
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.652e-1 (AD)  1.730e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FAM168B0.941
SERINC30.941
RAP1GDS10.939
MFN20.933
FBXO450.93
BCL2L20.929
APP0.928
STK390.927
GAS70.926
ARMCX30.923

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F29-0.626
OR4F5-0.585
RNF135-0.349
GJB2-0.337
PON3-0.335
MTRNR2L10-0.332
TGIF1-0.33
EYA2-0.329
EVC2-0.329
INHBB-0.325

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of VAPB mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPB mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPB mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of VAPB mRNA17562736
D000643Ammonium ChlorideAmmonium Chloride affects the expression of VAPB mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of VAPB mRNA24449571
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of VAPB mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of VAPB mRNA22342234
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of VAPB mRNA"19150397
D004958Estradiol[bisphenol A co-treated with Estradiol] results in decreased expression of VAPB mRNA26496021
C006780bisphenol Abisphenol A affects the expression of VAPB mRNA21786754
C006780bisphenol Abisphenol A affects the expression of VAPB mRNA25181051
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in decreased expression of VAPB mRNA26496021
C013418bromfenacoumbromfenacoum results in decreased expression of VAPB protein28903499
C073316carvacrolcarvacrol results in decreased expression of VAPB mRNA20008804
D000068579CelecoxibCelecoxib affects the expression of VAPB mRNA20562220
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of VAPB mRNA23650126
D002737ChloropreneChloroprene results in increased expression of VAPB mRNA23125180
D003042CocaineCocaine results in decreased expression of VAPB mRNA17898221
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of VAPB mRNA26924002
D004040Dietary CarbohydratesDietary Carbohydrates results in decreased expression of VAPB mRNA17490981
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene affects the expression of VAPB mRNA"21785161
C024629dimethyl phthalatedimethyl phthalate affects the expression of VAPB mRNA26924002
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of VAPB protein23301498
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of VAPB mRNA23649840
D018120FinasterideFinasteride results in increased expression of VAPB mRNA24136188
D005485FlutamideFlutamide results in increased expression of VAPB mRNA24136188
D005557FormaldehydeFormaldehyde results in increased expression of VAPB mRNA23649840
C001277geldanamycingeldanamycin results in increased expression of VAPB mRNA26705709
D007854LeadLead results in increased expression of VAPB mRNA19921347
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of VAPB mRNA25613284
D008727MethotrexateMethotrexate results in increased expression of VAPB mRNA24449571
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of VAPB mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of VAPB mRNA23649840
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of VAPB mRNA"20188158
C517284monomethyl phthalatemonomethyl phthalate affects the expression of VAPB mRNA26924002
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of VAPB mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog affects the expression of VAPB mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of VAPB mRNA"25620056
D010269ParaquatParaquat results in decreased expression of VAPB protein24521700
D010416PentachlorophenolPentachlorophenol results in increased expression of VAPB mRNA23892564
D013467SulindacSulindac results in increased expression of VAPB mRNA24136188
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of VAPB mRNA11007951
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VAPB mRNA21570461
D019284ThapsigarginThapsigargin results in decreased expression of VAPB protein24648495
D013849ThimerosalThimerosal results in decreased expression of VAPB mRNA27188386
C009495titanium dioxidetitanium dioxide results in decreased expression of VAPB mRNA23557971
D014241TrichloroethyleneTrichloroethylene results in increased methylation of VAPB gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of VAPB mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of VAPB mRNA24935251|2627250
D014635Valproic AcidValproic Acid affects the expression of VAPB mRNA17963808
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of VAPB gene25560391
C111237vorinostatvorinostat results in decreased expression of VAPB mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI9920726  16227268  18160438  18555774  19289470  21976701  
22131369  23736259  25616068  25910212  26496610  28377464  
GO:0008017microtubule binding-IDA18713837  
GO:0019899enzyme binding-IPI17540579  
GO:0033149FFAT motif binding-IMP18713837  
GO:0033149FFAT motif binding-IPI24105263  
GO:0042803protein homodimerization activity-IPI9920726  16227268  17540579  
GO:0045296cadherin binding-HDA25468996  
GO:0046982protein heterodimerization activity-IPI9920726  16227268  
GO:0048487beta-tubulin binding-IDA17540579  
GO ID GO Term Qualifier Evidence PubMed
GO:0006874cellular calcium ion homeostasis-IMP22131369  
GO:0006888ER to Golgi vesicle-mediated transport-IMP18713837  
GO:0007029endoplasmic reticulum organization-IMP18713837  
GO:0019048modulation by virus of host morphology or physiology-IDA16227268  
GO:0030148sphingolipid biosynthetic process-TAS-  
GO:0030968endoplasmic reticulum unfolded protein response-IMP16891305  
GO:0045070positive regulation of viral genome replication-IMP16227268  
GO:0090114COPII-coated vesicle budding-IMP18713837  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005737cytoplasm-IDA25468996  
GO:0005783endoplasmic reticulum-IDA15372378  16891305  18713837  
GO:0005789endoplasmic reticulum membrane-IDA16227268  
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0005794Golgi apparatus-IDA16227268  
GO:0016021integral component of membrane-IEA-  
GO:0070971endoplasmic reticulum exit siteNOTIDA18713837  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1660661Sphingolipid de novo biosynthesisTAS
R-HSA-428157Sphingolipid metabolismTAS
R-HSA-556833Metabolism of lipidsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23797033Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. (2013 Dec)D'Amico EFree Radic Biol Med